See more : Hexagon Purus ASA (HPURF) Income Statement Analysis – Financial Results
Complete financial analysis of Genocea Biosciences, Inc. (GNCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genocea Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Resources Cement Holdings Limited (CJRCF) Income Statement Analysis – Financial Results
- Hangzhou Jiebai Group Co., Limited (600814.SS) Income Statement Analysis – Financial Results
- BW LPG Limited (BWLLF) Income Statement Analysis – Financial Results
- Archosaur Games Inc. (9990.HK) Income Statement Analysis – Financial Results
- Ignyte Acquisition Corp. (IGNYU) Income Statement Analysis – Financial Results
Genocea Biosciences, Inc. (GNCA)
About Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.64M | 1.36M | 0.00 | 0.00 | 0.00 | 235.00K | 670.00K | 308.00K | 731.00K | 1.98M | 1.82M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.64M | 1.36M | 0.00 | 0.00 | 0.00 | 235.00K | 670.00K | 308.00K | 731.00K | 1.98M | 1.82M |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.02M | 33.96M | 26.95M | 25.21M | 39.20M | 33.05M | 28.05M | 23.73M | 15.70M | 11.24M | 13.54M |
| General & Administrative | 14.71M | 14.39M | 12.04M | 14.31M | 13.43M | 15.43M | 13.99M | 9.75M | 4.96M | 3.69M | 3.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.39M | 12.04M | 14.31M | 13.43M | 15.43M | 13.99M | 9.75M | 4.96M | 3.69M | 3.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 2.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.73M | 48.35M | 38.99M | 39.52M | 52.64M | 48.48M | 42.04M | 33.47M | 20.66M | 14.93M | 16.55M |
| Cost & Expenses | 53.73M | 48.35M | 38.99M | 39.52M | 52.64M | 48.48M | 42.04M | 33.47M | 20.66M | 14.93M | 16.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 410.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.12M | 1.38M | 946.00K | 1.02M | 1.71M | 1.74M | 1.12M | 970.00K | 459.00K | 507.00K | 33.00K |
| Depreciation & Amortization | 17.78M | 1.14M | 1.10M | 1.09M | 1.52M | 1.81M | 1.05M | 469.00K | 318.00K | 300.00K | 318.00K |
| EBITDA | -34.32M | -41.20M | -36.91M | -25.70M | -53.49M | -46.02M | -40.32M | -33.86M | -20.03M | -12.56M | -14.33M |
| EBITDA Ratio | -2,091.22% | -3,031.35% | 0.00% | 0.00% | 0.00% | -19,583.83% | -6,017.16% | -10,992.53% | -2,739.95% | -635.31% | -787.58% |
| Operating Income | -52.09M | -46.99M | -38.99M | -39.52M | -55.26M | -48.25M | -41.37M | -33.17M | -19.93M | -12.95M | -14.73M |
| Operating Income Ratio | -3,174.47% | -3,457.62% | 0.00% | 0.00% | 0.00% | -20,529.79% | -6,174.03% | -10,768.18% | -2,725.72% | -655.18% | -809.18% |
| Total Other Income/Expenses | 18.90M | 3.28M | 39.00K | 11.71M | -1.46M | -1.33M | -1.12M | -2.13M | -881.00K | -414.00K | 42.00K |
| Income Before Tax | -33.20M | -43.71M | -38.95M | -27.81M | -56.71M | -49.57M | -42.48M | -35.30M | -20.81M | -13.37M | -14.69M |
| Income Before Tax Ratio | -2,022.91% | -3,216.63% | 0.00% | 0.00% | 0.00% | -21,094.89% | -6,340.75% | -11,459.74% | -2,846.24% | -676.13% | -806.87% |
| Income Tax Expense | -17.78M | 4.66M | 985.00K | 12.73M | 250.00K | 410.00K | 0.00 | -1.16M | -422.00K | 93.00K | 75.00K |
| Net Income | -15.42M | -43.71M | -38.95M | -27.81M | -56.71M | -49.57M | -42.48M | -35.30M | -20.81M | -13.37M | -14.69M |
| Net Income Ratio | -939.67% | -3,216.63% | 0.00% | 0.00% | 0.00% | -21,094.89% | -6,340.75% | -11,459.74% | -2,846.24% | -676.13% | -806.87% |
| EPS | -0.22 | -0.94 | -1.89 | -2.69 | -15.86 | -14.01 | -13.89 | -18.08 | -9.67 | -14.31 | -11.68 |
| EPS Diluted | -0.22 | -0.94 | -1.89 | -2.69 | -15.86 | -14.01 | -13.89 | -18.08 | -9.67 | -14.31 | -11.68 |
| Weighted Avg Shares Out | 68.58M | 46.55M | 20.64M | 10.32M | 3.58M | 3.54M | 3.06M | 1.95M | 2.15M | 934.00K | 1.26M |
| Weighted Avg Shares Out (Dil) | 68.58M | 46.55M | 20.64M | 10.32M | 3.58M | 3.54M | 3.06M | 1.95M | 2.15M | 934.00K | 1.26M |
Atlas Selected as the Search and Rescue Unmanned Aerial System for Norwegian Arctic SAR Unit NPAID
Atlas Selected to Lead Sherwood Forest Drive Extension Project in Louisiana
Is she winning?
Boston Dynamics' robot dog inspects SpaceX site in Texas
Un líder solvente y más ruido
Grande
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Will The LHC Be Humanity's Last Gasp For Particle Physics?
HSCM Bermuda recapitalises fronting insurer for auto insurtech Buckle - Artemis.bm
Source: https://incomestatements.info
Category: Stock Reports